DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Systemic Lupus Erythematosus | Treatment Algorithms | Claims Data Analysis | US | 2019
Hydroxychloroquine, corticosteroids, and conventional immunosuppressants are the mainstay of treatment for systemic lupus erythematosus (SLE), a chronic, complex autoimmune disease affecting…
Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Adult | US | 2019
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Ulcerative Colitis | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2019
MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α)…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 3 | 2019
Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA) and the only other oral targeted therapy besides Celgene’s PDE-4 inhibitor, Otezla, approved for this indication…
Alzheimer’s Disease | Treatment Algorithms: Claims Data Analysis | Neuropsychiatric Therapies in Alzheimer’s Disease | US | 2019
Alongside putative disease-modifying therapies, the late-phase pipeline in Alzheimer’s disease (AD) features several therapies for the treatment of behavioral symptoms in AD. Symptoms such as…
Rheumatoid Arthritis | Emerging Therapies | Olumiant (baricitinib) | US | Wave 2 | 2019
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
Noninfectious Uveitis of the Posterior Segment | Treatment Algorithms: Claims Data Analysis | US | 2019
Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis…
Dry and Wet Age-Related Macular Degeneration | Treatment Algorithms: Claims Data Analysis | Wet Age-Related Macular Edema | US | 2019
The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…
